Here we characterize leukocyte mono-Ig-like receptor 7 (LMIR7)/CLM-3 and compare it with an activating receptor, LMIR4/CLM-5, that is a counterpart of an inhibitory receptor LMIR3/CLM-1. LMIR7 shares high homology with LMIR4 in the amino acid sequences of its Ig-like and transmembrane domains. Flow cytometric analysis demonstrated that LMIR4 was predominantly expressed in neutrophils, whereas LMIR7 was highly expressed in mast cells and monocytes/macrophages. Importantly, LMIR7 engagement induced cytokine production in bone marrow-derived mast cells (BMMCs). Although FcR␥ deficiency did not affect surface expression levels of LMIR7, it abolished LMIR7-mediated activation of BMMCs. Consistently we found significant interaction of LMIR7-FcR␥, albeit with lower affinity compared with that of LMIR4-FcR␥. Our results showed that LMIR7 transmits an activating signal through interaction with FcR␥. In addition, like LMIR4, LMIR7 synergizes with TLR4 in signaling. Analysis of several chimera receptors composed of LMIR4 and LMIR7 revealed these findings: 1) the transmembrane of LMIR7 with no charged residues maintained its surface expression at high levels in the absence of FcR␥; 2) the extracellular juxtamembrane region of LMIR7 had a negative effect on its surface expression levels; and 3) the strong interaction of LMIR4 with FcR␥ depended on the extracellular juxtamembrane region as well as the transmembrane domain of LMIR4. Thus, LMIR7 shares similarities with LMIR4, although they are differentially regulated in their distribution, expression, and function.A new family of paired immunoreceptors has been recently identified and named leukocyte mono-Ig-like receptor (LMIR) 3 /CMRF-35-like molecules (CLM)/myeloid-associated Ig-like receptor (MAIR)/dendritic cell-derived Ig-like receptor (DIgR)/immune receptor expressed by myeloid cell (IREM)/ CD300 (1-15). In mice, there exist at least eight members of the LMIR family (1-9). We and others have previously characterized LMIR1-5 (1-8). An inhibitory receptor, LMIR3/CLM-1, pairs with an activating receptor, LMIR4/CLM-5 or LMIR5/ CLM-7. LMIR3 is 91 and 53% identical with LMIR4 and LMIR5, respectively, in the amino acid sequence of the Ig-like domain. In addition, LMIR4 and LMIR5 transmits an activating signal through interaction with FcR␥ and DAP12, respectively (2, 3). Consistently, LMIR5 has a positively charged residue (lysine) in the transmembrane domain, which is characteristic of activating receptors interacting with adaptors containing ITAM (3). However, LMIR4 does not have a positively charged residue in the transmembrane domain; instead, it has a negatively charged residue (glutamic acid) (2, 8). Interestingly, the inhibitory receptor LMIR3 also has the potential to transmit an activating signal through interaction with FcR␥ in mast cells, despite having no charged residue in the transmembrane domain (4).FcR␥ is an ITAM-bearing signal transduction subunit expressed in a variety of hematopoietic cells (15)(16)(17)(18)(19). It is an essential component of the high affi...